Skip to content

Media
Investors

Media
Investors

TAMP Therapy Platform
- Our Science
- RenovoCath®
For Physicians
- Evidence
- Resources
For Patients
About Us
Contact
Media
Investors

TAMP Therapy Platform
- Our Science
- RenovoCath®
For Physicians
- Evidence
- Resources
For Patients
About Us
Contact
Media
Investors

Day: November 14, 2022

RenovoRx Reports Third Quarter 2022 Financial Results

RenovoRx today reported its financial results for the quarter ended September 30, 2022.

RenovoCath is FDA-cleared for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of Locally Advanced Pancreatic Cancer (LAPC) in an ongoing clinical trial conducted under an IND.

Facebook-f X-twitter Linkedin-in Youtube

Menu

TAMP Therapy Platform
Our Science
RenovoCath®
Physicians
Evidence
Clinical Trials
Patients
The Procedure
FAQs
Patient Stories
Physician Locator
About
Leadership
Board of Directors
Advisory Boards
Contact

TAMP Therapy Platform
Our Science
RenovoCath®
Physicians
Evidence
Clinical Trials
Patients
The Procedure
FAQs
Patient Stories
Physician Locator
About
Leadership
Board of Directors
Advisory Boards
Contact

2570 W. El Camino Real, Suite 640
Mountain View, CA 94040
(650) 284-4433
info@renovorx.com

© 2026 RenovoRx®. All rights reserved.

Privacy Statement | Terms of Use